期刊文献+

卫生经济学分析的系统评价方法与挑战 被引量:3

Systematic Review of Economic Analyses: Methods and Challenges
下载PDF
导出
摘要 卫生经济学分析的系统评价借鉴随机对照试验系统评价的基本原则和方法,整合针对某一疾病的某些干预措施的所有相关经济学研究,系统分析不同经济学分析研究结果的差异,为决策提供经济学综合分析证据。它主要包括以下7个步骤:①形成研究问题;②确定筛选标准;③文献检索与筛选;④文献质量评价;⑤数据获取;⑥数据分析与综合;⑦结果报告。但由于卫生经济学研究的特殊性,其系统评价也面临明显的方法学问题与挑战,诸如经济学分析模型、分析角度、研究时间范围、不确定性处理和敏感度分析方法等差异给证据评价、合成带来了明显的异质性,而且更需要关注合成证据结果的外推性。 Based on the principles and methods of systematic review of randomized controlled clinical trials, systematic review of economic analyses can integrate information from multiple economic studies which focus on the same clinical questions. It can also provide important insights by systematically examining how differences among studies lead to different results. Generally, there are seven steps to conduct such a review: 1) formulating questions; 2) establishing eligibility criteria; 3) searching and selecting eligible economic analyses; 4) assessing the validity of economic analyses; 5) acquiring data; 6) analyzing and synthesizing data; and 7) presenting results. Owing to the specificity of economic analyses, many methodological challenges exist, including the varieties of economic models, analytic perspectives, time horizons, and uncertainty and sensitivity analysis among different economic analyses. This may cause difficulties for critical assessment of the economic analyses.
出处 《中国循证医学杂志》 CSCD 2008年第11期1007-1011,共5页 Chinese Journal of Evidence-based Medicine
基金 国家自然科学基金面上项目"上市后药物循证评价指标体系与方法学模式研究"资助(项目编号:70503021)
关键词 卫生经济学 系统评价 方法学 Health economics Systematic review Methodology
  • 相关文献

参考文献16

  • 1Shemilt I, Mugford M, Byford S. Incorporating economics evidence. In: Higgins JPT, Green S. Handbook for Systematic Reviews of Interventions (Version 5.0.0). 2008. http://www.cochranehandbook.org/.
  • 2孙鑫,Ewa Orlewska,李幼平,杨焕,鄢琳.上市后药物经济学评价方法(Ⅰ)——建立经济学评价框架,评价经济学证据(英文)[J].中国循证医学杂志,2005,5(12):944-949. 被引量:3
  • 3Mugford M. Using Systematic Reviews for Economic Evaluations. Systematic Reviews in Health Care. London: BMJ Publishing, 2001.
  • 4Centre for Reviews and Dissemination, University of York, UK. NHS economic evaluation database handbook. 2007.
  • 5Centre for Reviews and Dissemination. http://www.crd.york.ac.uk/ crdweb.
  • 6Cochrane library, http://www.thecochranelibrary.org.
  • 7Cost-effectiveness analysis registry. Harvard University. https:// research.tufts-nemc.org/cear/default.aspx.
  • 8Drummond MF, Stoddardt GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1987, p18-38.
  • 9Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ, 1996, 313(7052): 275-283.
  • 10Siegel JE, Weinstein MC, Russell LB, et al. Recommendations for reporting cost-effectiveness analyses. JAMA, 1996, 276(16): 1339-1341.

二级参考文献23

  • 1Fox AW.Phase II and phase III clinical studies.In:Fletcher AJ,Edwards L,Fox AW,Stonier P eds.Principles and practices of pharmaceutical medicine.John Wiley & Sons,Ltd.2002
  • 2Edwards R,Olsson S.WHO Programme - Global Monitoring.In:Mann RD,Andrews EB.Pharmacovigilance.John Wiley & Sons,Ltd.2002.
  • 3Johnson-Pratt LR.Phase IV drug development:post-marketing studies.In:Fletcher AJ,Edwards L,Fox AW,Stonier P eds.Principles and practices of pharmaceutical medicine.John Wiley & Sons,Ltd.2002.
  • 4Che MF,Han BS.The preparation and implementation of essential medicines list in China.Chinese Pharmaceutical Issues.2000;14(1):19-21.
  • 5Xu FK.The selection of essential medicines in China.Chinese Hospital Management.1997;17(4):23-24.
  • 6Li SL,Cao LY,Xiao AL,Yan L,Lan F.Evidence-based evaluation of essential medicines.Chinese Pharmaceutical Issues.2003;17(6):337-339.
  • 7Data from OECD Health Database.Available from http://www.euro.who.int/document/e73096.pdf.
  • 8Data from the Chinese Ministry of Health.Available from:http://61.49.18.68/statistics/digest03/t33.htm.
  • 9Sun X,Li YP,Cao LY,Wiffen P.A perspective of evidence-based medicine on post-marketing drug evaluation in China:present,problems and strategies.The 8th Global Health Forum.Mexico City,Mexico.2004.
  • 10Canadian Coordinating Office for Health Technology Assessment.Guidelines for economic evaluation of pharmaceuticals:Canada.2nd Edition.November 1997.

共引文献2

同被引文献61

  • 1张志萍,朱秀美,郭代红,任浩洋,卓贵华,王锦军.急性非淋巴性白血病3种治疗方案的成本效果分析[J].中国药物应用与监测,2001(2):9-10. 被引量:1
  • 2Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of Child mortality in 2008: a systematic analysis. Lancet, 2010, 375 (9730) : 1969-1987.
  • 3Martin JA, Hamilton BE, Menacker F, et al. Prelimlnary births for 2004: infant and maternal health, http://www, cdc. gov/ nchs/products/pubs/pubd/hestats/prelimbirths04/prelimbirths 04health. htm.
  • 4WHO. World Health Statistics 2010. http://www, who. int./ whosis/whostat/2010/en/index, html.
  • 5I Ministry of Health of the People Republic of China. The 2011 Statistic Bulletin of Chinese medical health development, http://www, moh. gov. cn/publicfiles/ business/htmlfiles/mohwsbwstjxxzx,/s7967/201204/54532, htm.
  • 6Sun B, Ma L, Liu XH, et al. Development of neonatal respiratory and intensive care : Chinese perspectives. Neonatology, 2012, 101 (2) :77-82.
  • 7Dukhovny D, Zupancic JA. Economic evaluation with clinical trials in neonatology. Neoviews, 2011, 12(2) : e69-75.
  • 8Drummond MF, Jefferson TO. Guidelines for authors and peerreviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ, 1996, 313(7052) : 275 -283.
  • 9Lee SK, Zupancic JA, Sale J, et al. Cost-effectiveness and choice of infant transport systems. Med Care, 2010, 40 (8) : 705 -716.
  • 10Dukhovny D, Lorch SA, Schmidt B, et al. Economic evaluation of caffeine for apnea of prematurity. Pediatrics, 2011, 127 ( 1 ) : e146-155.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部